Le Lézard
Classified in: Health
Subjects: NPT, CHI, TDS, FVT

STEM3 Academy Announces Second Annual 'Very Special Innovation Fair'



LOS ANGELES, Oct. 5, 2017 /PRNewswire/ -- The Help Group's STEM3 Academy, the first school in the nation to provide a STEM curriculum to students with special needs, announces its second annual Very Special Innovation Fair ? equal parts science fair, high-tech exhibition, art show, and community carnival. The free event will be a family-friendly celebration of talent, imagination, and discovery from young STEM enthusiasts, as well as some of the region's innovative companies. Last year's event proved to be very successful with 500+ in attendance. This year's event is expected to draw a big crowd again.

The Help Group. (PRNewsFoto/The Help Group)

Inspired in part by the Maker Movement, there will be interactive opportunities for young people and families to build things, get involved in experiments and demonstrations, and take various gadgets for a 'test drive.'

According to Dr. Susan Berman, COO of The Help Group, "We're focused on developing strategies and fun programming for young people with social and learning differences that encourage a passion for STEM."

The school is hosting the fair to help people learn about the exciting things happening in STEM and how it is playing an increasing role in fields as diverse as manufacturing, medicine, design, and entertainment, among others. 

Dr. Ellis Crasnow, Director of STEM³ Academy and STEM Education at The Help Group says, "Our goal at STEM3 Academy and with the Very Special Innovation Fair is to help nurture those natural talents early on."

The Very Special Innovation Fair will take place Saturday, November 4 from 10:00 a.m. to 2:00 p.m. at STEM3 Academy - 6455 Coldwater Canyon, Valley Glen. For more information on attending, sponsoring, or exhibiting at the Very Special Innovation Fair, visit www.innovationfair.stem3academy.org.

To read the full press release, click here.

About STEM3 Academy
STEMAcademy is designed for students with social or learning differences who have a passion for STEM fields. The school offers a comprehensive and integrated college preparatory curriculum, focusing on the long-term development, strength and needs of each student. www.STEM3Academy.org

About The Help Group:
Founded in 1975, The Help Group is the largest, most innovative and comprehensive nonprofit of its kind in the United States serving children, adolescents and young adults with special needs related to autism spectrum disorder, learning disabilities, ADHD, developmental delays, abuse and emotional challenges. www.thehelpgroup.org

SOURCE The Help Group


These press releases may also interest you

at 03:00
SAN FRANCISCO, Dec. 13, 2017 /PRNewswire-PRWeb/ -- First Opinion, Inc. announced today it has acquired Incente, LLC, a behavioral health technology company based in Hanover, NH. In addition to the acquisition, First Opinion also announced the...

at 02:44
NeuroVive Pharmaceutical AB, announced today that the European Commission has granted orphan drug designation (ODD) for the company's KL1333 program for oral treatment of the genetic mitochondrial disease Mitochondrial Myopathy, Encephalopathy,...

at 02:00
A Sioux Falls company, OmegaQuant, LLC has reached an agreement with the Office of In Vitro Diagnostics and Radiological Health of the Food and Drug Administration (FDA) that allows OmegaQuant to market its Omega-3 Indextm test as an over the...

at 02:00
Provide your body with the support it needs to fight the effects of oxidative stress.* Pure Encapsulations® Nrf2 Detox with Setria® Glutathione is now available in Germany and Austria. Nrf2 Detox is a three-ingredient blend that contains broccoli...

at 01:30
Regeneron Pharmaceuticals, Inc. today announced updates related to its collaboration programs with Sanofi, which were highlighted during Sanofi's Sustaining Innovation Analyst Day in Paris, France. In a separate release today the companies also...

at 01:01
Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive topline results from a pivotal Phase 2 clinical study of cemiplimab in 82 patients with advanced cutaneous squamous cell carcinoma (CSCC), the second deadliest skin cancer after...




News published on 5 october 2017 at 09:05 and distributed by: